BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25972334)

  • 1. Loss of BAP1 Expression in Basal Cell Carcinomas in Patients With Germline BAP1 Mutations.
    Mochel MC; Piris A; Nose V; Hoang MP
    Am J Clin Pathol; 2015 Jun; 143(6):901-4. PubMed ID: 25972334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline BAP1 mutations predispose also to multiple basal cell carcinomas.
    de la Fouchardière A; Cabaret O; Savin L; Combemale P; Schvartz H; Penet C; Bonadona V; Soufir N; Bressac-de Paillerets B
    Clin Genet; 2015 Sep; 88(3):273-7. PubMed ID: 25080371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumours associated with BAP1 mutations.
    Murali R; Wiesner T; Scolyer RA
    Pathology; 2013 Feb; 45(2):116-26. PubMed ID: 23277170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma.
    Wadt KA; Aoude LG; Johansson P; Solinas A; Pritchard A; Crainic O; Andersen MT; Kiilgaard JF; Heegaard S; Sunde L; Federspiel B; Madore J; Thompson JF; McCarthy SW; Goodwin A; Tsao H; Jönsson G; Busam K; Gupta R; Trent JM; Gerdes AM; Brown KM; Scolyer RA; Hayward NK
    Clin Genet; 2015 Sep; 88(3):267-72. PubMed ID: 25225168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
    Piris A; Mihm MC; Hoang MP
    Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal cell carcinomas developing independently from BAP1-tumor predisposition syndrome in a patient with bilateral uveal melanoma: Diagnostic challenges to identify patients with BAP1-TPDS.
    Melzer C; Sharma A; Peters S; Aretz S; Biswas A; Holz FG; Loeffler KU; Herwig-Carl MC
    Genes Chromosomes Cancer; 2019 Jun; 58(6):357-364. PubMed ID: 30578689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histomorphologic spectrum of germline-related and sporadic BAP1-inactivated melanocytic tumors.
    Garfield EM; Walton KE; Quan VL; VandenBoom T; Zhang B; Kong BY; Isales MC; Panah E; Kim G; Gerami P
    J Am Acad Dermatol; 2018 Sep; 79(3):525-534. PubMed ID: 29753057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.
    Costa S; Byrne M; Pissaloux D; Haddad V; Paindavoine S; Thomas L; Aubin F; Lesimple T; Grange F; Bonniaud B; Mortier L; Mateus C; Dreno B; Balme B; Vergier B; de la Fouchardiere A
    Am J Surg Pathol; 2016 Mar; 40(3):368-77. PubMed ID: 26645730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation.
    Gerami P; Yélamos O; Lee CY; Obregon R; Yazdan P; Sholl LM; Guitart GE; Njauw CN; Tsao H
    JAMA Dermatol; 2015 Nov; 151(11):1235-9. PubMed ID: 26154183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer.
    McDonnell KJ; Gallanis GT; Heller KA; Melas M; Idos GE; Culver JO; Martin SE; Peng DH; Gruber SB
    Cancer Genet; 2016 Mar; 209(3):75-81. PubMed ID: 26774355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
    Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
    Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series.
    Aung PP; Nagarajan P; Tetzlaff MT; Curry JL; Tang G; Abdullaev Z; Pack SD; Ivan D; Prieto VG; Torres-Cabala CA
    Am J Dermatopathol; 2019 Mar; 41(3):167-179. PubMed ID: 30801340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome.
    Marušić Z; Buljan M; Busam KJ
    J Cutan Pathol; 2015 Jun; 42(6):406-12. PubMed ID: 25902915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population-based analysis of germline BAP1 mutations in melanoma.
    O'Shea SJ; Robles-Espinoza CD; McLellan L; Harrigan J; Jacq X; Hewinson J; Iyer V; Merchant W; Elliott F; Harland M; Bishop DT; Newton-Bishop JA; Adams DJ
    Hum Mol Genet; 2017 Feb; 26(4):717-728. PubMed ID: 28062663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.
    Ewens KG; Lalonde E; Richards-Yutz J; Shields CL; Ganguly A
    BMC Cancer; 2018 Nov; 18(1):1172. PubMed ID: 30477459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.
    Star P; Goodwin A; Kapoor R; Conway RM; Long GV; Scolyer RA; Guitera P
    Eur J Cancer; 2018 Mar; 92():48-53. PubMed ID: 29413689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.
    Haugh AM; Njauw CN; Bubley JA; Verzì AE; Zhang B; Kudalkar E; VandenBoom T; Walton K; Swick BL; Kumar R; Rana HQ; Cochrane S; McCormick SR; Shea CR; Tsao H; Gerami P
    JAMA Dermatol; 2017 Oct; 153(10):999-1006. PubMed ID: 28793149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
    Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
    Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
    Soares de Sá BC; de Macedo MP; Torrezan GT; Braga JCT; Fidalgo F; Moredo LF; Lellis R; Duprat JP; Carraro DM
    BMC Cancer; 2019 Nov; 19(1):1077. PubMed ID: 31706282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.
    Njauw CN; Kim I; Piris A; Gabree M; Taylor M; Lane AM; DeAngelis MM; Gragoudas E; Duncan LM; Tsao H
    PLoS One; 2012; 7(4):e35295. PubMed ID: 22545102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.